ADAPTIVE BIOTECHNOLOGIES CORP financial statements (2022 and earlier)

Company profile

Business Address 1551 EASTLAKE AVENUE EAST SUITE 200
SEATTLE, WA 98102
State of Incorp. WA
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments688577
Cash and cash equivalents12397
Short-term investments565480
Receivables1115
Inventory, net of allowances, customer advances and progress billings149
Inventory149
Other undisclosed current assets1412
Total current assets:727613
Noncurrent Assets
Operating lease, right-of-use asset99 
Property, plant and equipment4060
Long-term investments and receivables119105
Long-term investments119105
Intangible assets, net (including goodwill)129131
Goodwill119119
Intangible assets, net (excluding goodwill)1012
Restricted cash and investments22
Other noncurrent assets11
Total noncurrent assets:390300
TOTAL ASSETS:1,116912
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2817
Accounts payable34
Accrued liabilities134
Employee-related liabilities128
Deferred revenue7361
Deferred rent credit 0
Other undisclosed current liabilities4 
Total current liabilities:10578
Noncurrent Liabilities
Long-term debt and lease obligation10437
Finance lease, liability 37
Operating lease, liability104 
Liabilities, other than long-term debt164226
Deferred revenue164219
Deferred rent credit 7
Other liabilities 0
Total noncurrent liabilities:268263
Total liabilities:373341
Stockholders' equity
Stockholders' equity attributable to parent743571
Common stock00
Additional paid in capital1,254936
Accumulated other comprehensive income11
Accumulated deficit(512)(365)
Total stockholders' equity:743571
TOTAL LIABILITIES AND EQUITY:1,116912

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
Revenues9885
Cost of revenue
(Cost of Goods and Services Sold)
(23)(22)
Gross profit:7663
Operating expenses(229)(141)
Operating loss:(153)(78)
Loss from continuing operations before income taxes:(153)(78)
Income tax expense (2)
Loss before gain (loss) on sale of properties:(153)(80)
Other undisclosed net income712
Net loss attributable to parent:(146)(69)
Preferred stock dividends and other adjustments (1)
Net loss available to common stockholders, diluted:(146)(70)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
Net loss:(146)(69)
Comprehensive loss:(146)(69)
Other undisclosed comprehensive income, net of tax, attributable to parent01
Comprehensive loss, net of tax, attributable to parent:(146)(68)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: